Urothelial Cancer Drugs Market

Urothelial Cancer Drugs Market by Treatments (Chemotherapy and Immunotherapy) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.

  • Report ID: HC-1984
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 210
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global urothelial cancer drugs market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the existence of a strong pipeline, availability of novel drugs, and growing incidence of urothelial cancer among the rising geriatric population. Additionally the changed lifestyle and rising public awareness are major driving factors for the market growth.

Urothelial Cancer Drugs Market Key Takeaways

A type of tumor formation in the bladder is called as urothelial carcinoma and is also known as transitional cell carcinoma. It is a type of malignant neoplasm arising from urothelium that can affect other parts of the body without proper treatment and therapy. The urothelium is inner lining of the urethra, bladder, and ureters. The cancer type is broadly classified into three classes: the early stage or non-muscle invasive bladder cancer (NMIBC), the mid-stage or muscle-invasive bladder cancer disease (MIBC), and the late-stage called metastatic disease. As per a global health report, about 70% of patients are of NMIBC, 20% are of the MIBC, and 10% at the late stage.

As per Globocan 2020, the disease ranks as 10th most common malignancy disease worldwide, with around 2.4 million cases and 419,000 newly detected patients recorded every year. Bladder urothelial carcinoma is responsible for nearly 90% of all urinary cancer patients. According to the report of the International Agency for Research on Cancer (IARC), 60% of all bladder cancer cases are witnessed in developed countries such as the US and some countries of Europe while Belgium tops the list with the highest number of bladder cancer cases.

The COVID-19 pandemic has had an intense impact on the urothelial cancer drugs market. According the statistics reported by the National Health Services, England in 2020, on topic 'NHS Diagnostic Waiting Times and Activity Data', the healthcare facilities of the cancer treatment had been shattered worldwide due to the rising shift of the pharmaceutical companies to solve huge burden of COVID-19 pandemic at the first place. Cancer patients are witnessing several concerns such as increase of the waiting time for cancer diagnostic procedures in hospitals and clinics. In August 2020, around 50% of cases in England for cystoscopy was forced to wait for minimum of six weeks against the 9% in 2019. This great impact in diagnosis showed negative impact on the treatment of the disease as well.

Market Trends, Drivers, Restraints, and Opportunities

  • Surging numbers of cases suffering from urothelial cancer and large recurrence rate of patients among geriatric population across the world are major driving factors for the market.
  • Increasing awareness among the population and initiatives by government and non-government organizations for early diagnosis of cancer are propelling the market growth.
  • High number of new drug approvals in the field along with large funding for the research and development activities presents a major factor for the overall market growth.
  • Availability of significant number of generic drugs in the market and high expenditure on R&D are proving to be major restraints to the market.
  • Rising concerns related to the side effects associated with chemotherapy is a challenge that can hamper the market expansion in the coming future.
  • Advanced technology for the development of new drugs is offering great opportunities for the market in the near future.

Scope of the Report

The report on the global urothelial cancer drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Urothelial Cancer Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Treatments (Chemotherapy and Immunotherapy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Regeneron Pharmaceuticals, Inc.; Pfizer, Inc.; GlaxoSmithKline plc.; Genentech; Bristol-Myers Squibb Co.; Sanofi; F. Hoffmann-La Roche Ltd; Novartis AG; Merck KGaA; Eli Lilly and Co.; AstraZeneca; Exelixis, Inc.; Immunomedics; UroGen Pharma, Inc.; Johnson & Johnson Services, Inc.; Astellas Pharma US, Inc.; Janssen Biotech, Inc.; Sitka Biopharma; and Sesen Bio

Market Segment Insights

Chemotherapy segment is expected to grow at a considerable pace

Based on treatments, the global urothelial cancer drugs market is bifurcated into chemotherapy and immunotherapy. The chemotherapy segment is expected to grow at a considerable pace during the forecast period considering the factors that the chemotherapy can be used alone as well as in the combination therapy when needed. Chemotherapy is used to reduce or stop the development of cancer cells and is the most commonly adopted form of treatment. The treatment works on the whole body to damage and destroy cancer cells so that the spread of cancer cells to the other parts of the body can be prevented. The rising approvals of new drugs is a significant driver for the segment. For example, the United States Food and Drug Administration (FDA) approved Padcev, which was developed by Astellas Pharma US Inc. coupled with Seattle Genetics Inc. in December 2019.

The immunotherapy segment, however, is projected to register substantial growth in the coming years owing to the high research and development in the field as well as the positive results of the clinical trials of the treatment technique.

Urothelial Cancer Drugs Market By Treatments

North America is anticipated to dominate the market
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the North America is anticipated to dominate the market during the forecast period owing to the factors including availability of large targeted patients, increased drug approvals, adoption of novel therapeutics, and high funding in the region. According to GLOBOCAN, around 90,000 new patients of bladder cancer were diagnosed in North America, in 2020 and this number was anticipated to reach around 136,000 in 2045. So, this high probability of increasing incidence of the disease in the region provides high opportunity for the growth of the market in the near future.

Meanwhile, the market of Asia Pacific is projected to grow with a substantial pace as the region has witnessed a large number of population with urothelial cancer. Along with the high rate of research activities and increased drug approvals, the rising government initiatives for public awareness campaign related to various types of cancer is pushing the market growth in the region.

Urothelial Cancer Drugs Market By Regions

Segments

Segments Covered in the Report
The global urothelial cancer drugs market has been segmented on the basis of

Treatments
  • Chemotherapy
  • Immunotherapy
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • GlaxoSmithKline plc.
  • Genentech
  • Bristol-Myers Squibb Co.
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck KGaA
  • Eli Lilly and Co.
  • AstraZeneca
  • Exelixis, Inc.
  • Immunomedics
  • UroGen Pharma, Inc.
  • Johnson & Johnson Services, Inc.
  • Astellas Pharma US, Inc.
  • Janssen Biotech, Inc.
  • Sitka Biopharma
  • Sesen Bio

Competitive Landscape

Key players competing in the global urothelial cancer drugs market are Regeneron Pharmaceuticals, Inc.; Pfizer, Inc.; GlaxoSmithKline plc.; Genentech; Bristol-Myers Squibb Co.; Sanofi; F. Hoffmann-La Roche Ltd; Novartis AG; Merck KGaA; Eli Lilly and Co.; AstraZeneca; Exelixis, Inc.; Johnson & Johnson Services, Inc.; Immunomedics; UroGen Pharma, Inc.; Astellas Pharma US, Inc.; Janssen Biotech, Inc.; Sitka Biopharma; and Sesen Bio.

Merck and AstraZeneca are anticipated to top the market in 2023, which is bolstered by approvals of Keytruda + chemotherapy and Imfinzi + tremelimumab regimens in early stages of treatment for both chemo-eligible and chemo-ineligible cases.

Urothelial Cancer Drugs Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Urothelial Cancer Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Urothelial Cancer Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Urothelial Cancer Drugs Market - Supply Chain
  4.5. Global Urothelial Cancer Drugs Market Forecast
     4.5.1. Urothelial Cancer Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Urothelial Cancer Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Urothelial Cancer Drugs Market Absolute $ Opportunity
5. Global Urothelial Cancer Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Urothelial Cancer Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Urothelial Cancer Drugs Demand Share Forecast, 2019-2026
6. North America Urothelial Cancer Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Urothelial Cancer Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Urothelial Cancer Drugs Demand Share Forecast, 2019-2026
7. Latin America Urothelial Cancer Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Urothelial Cancer Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Urothelial Cancer Drugs Demand Share Forecast, 2019-2026
8. Europe Urothelial Cancer Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Urothelial Cancer Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Urothelial Cancer Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Urothelial Cancer Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Urothelial Cancer Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Urothelial Cancer Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Urothelial Cancer Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Urothelial Cancer Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Urothelial Cancer Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Urothelial Cancer Drugs Market: Market Share Analysis
  11.2. Urothelial Cancer Drugs Distributors and Customers
  11.3. Urothelial Cancer Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Regeneron Pharmaceuticals, Inc. Pfizer, Inc. GlaxoSmithKline plc. Genentech Bristol-Myers Squibb Co. Sanofi
Segments Covered in the Report
The global urothelial cancer drugs market has been segmented on the basis of

Treatments
  • Chemotherapy
  • Immunotherapy
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • GlaxoSmithKline plc.
  • Genentech
  • Bristol-Myers Squibb Co.
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck KGaA
  • Eli Lilly and Co.
  • AstraZeneca
  • Exelixis, Inc.
  • Immunomedics
  • UroGen Pharma, Inc.
  • Johnson & Johnson Services, Inc.
  • Astellas Pharma US, Inc.
  • Janssen Biotech, Inc.
  • Sitka Biopharma
  • Sesen Bio

Key players competing in the global urothelial cancer drugs market are Regeneron Pharmaceuticals, Inc.; Pfizer, Inc.; GlaxoSmithKline plc.; Genentech; Bristol-Myers Squibb Co.; Sanofi; F. Hoffmann-La Roche Ltd; Novartis AG; Merck KGaA; Eli Lilly and Co.; AstraZeneca; Exelixis, Inc.; Johnson & Johnson Services, Inc.; Immunomedics; UroGen Pharma, Inc.; Astellas Pharma US, Inc.; Janssen Biotech, Inc.; Sitka Biopharma; and Sesen Bio.

Merck and AstraZeneca are anticipated to top the market in 2023, which is bolstered by approvals of Keytruda + chemotherapy and Imfinzi + tremelimumab regimens in early stages of treatment for both chemo-eligible and chemo-ineligible cases.

Urothelial Cancer Drugs Market By Key Players

Buy Report